Dino A. Rossi - 19 Feb 2026 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Role
Director
Signature
/s/ Krish Krishnan, as attorney-in-fact for Dino A. Rossi
Issuer symbol
KRYS
Transactions as of
19 Feb 2026
Net transactions value
-$4,787,124
Form type
4
Filing time
23 Feb 2026, 19:14:37 UTC
Previous filing
30 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ROSSI DINO A Director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH /s/ Krish Krishnan, as attorney-in-fact for Dino A. Rossi 23 Feb 2026 0001209059

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Options Exercise $166,570 +18,950 +24% $8.79 97,641 19 Feb 2026 Direct
transaction KRYS Common Stock Sale $2,114,103 -8,116 -8.3% $260.49 89,525 19 Feb 2026 Direct
transaction KRYS Common Stock Sale $2,839,591 -10,834 -12% $262.10 78,691 19 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRYS Stock Option (Right to Buy) Options Exercise $0 -18,950 -100% $0.000000 0 19 Feb 2026 Common Stock 18,950 $8.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Multiple lots for the same price for this transaction have been combined.
F2 The options vested ratably over a four-year period beginning on June 1, 2018.